SCHEMBL7976885

SCHEMBL7976885

Cc1nc2cc(Cl)ccn2c1C(=O)/C=C/N(C)C

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.46
ALDH1A1 P00352 5/20 0.46
HTT P42858 4/20 0.46
HPGD P15428 2/20 0.46
GAA P10253 2/20 0.46
KMT2A Q03164 2/20 0.44
SMN1; SMN2 Q16637 8/20 0.44
RAB9A P51151 7/20 0.44
LMNA P02545 6/20 0.44
NPC1 O15118 5/20 0.44
CYP1A2 P05177 1/20 0.43
ALOX12 P18054 1/20 0.43
CYP2C19 P33261 1/20 0.43
POLB P06746 4/20 0.41
NPSR1 Q6W5P4 1/20 0.41
MITF O75030 1/20 0.40
MAPK1 P28482 1/20 0.39
MEN1 O00255 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7964745 0.83 MAPT (0.52) MAPTALDH1A1HTTHPGDGAA
SCHEMBL7981635 0.81 MAPT (0.43) MAPTALDH1A1HTTHPGDGAA
SCHEMBL7964747 0.81 LMNA (0.65) MAPTALDH1A1HTTHPGDGAA
SCHEMBL7978700 0.78 KMT2A (0.60) MAPTALDH1A1HTTGAAKMT2A
SCHEMBL19723682 0.77 SMN1; SMN2 (0.49) MAPTALDH1A1HTTGAAKMT2A
SCHEMBL23574175 0.75 SMN1; SMN2 (0.47) MAPTALDH1A1HTTGAAKMT2A
SCHEMBL27217434 0.73 ALDH1A1 (0.43) MAPTALDH1A1HTTHPGDGAA
SCHEMBL10255400 0.72 ALDH1A1 (0.41) MAPTALDH1A1HTTHPGDGAA
SCHEMBL3755232 0.72 SMN1; SMN2 (0.51) MAPTALDH1A1HTTHPGDGAA
SCHEMBL3755236 0.72 SMN1; SMN2 (0.51) MAPTALDH1A1HTTHPGDGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8124764-B2 Fused heterocyclyc inhibitor compounds GILEAD SCIENCES, INC. (US) 2012-02-28 US disclosed
US-8124764-B2 Fused heterocyclyc inhibitor compounds GILEAD SCIENCES, INC. (US) 2012-02-28 US disclosed
US-20100029638-A1 FUSED HETEROCYCLYC INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. 2010-02-04 US disclosed
US-20100029638-A1 FUSED HETEROCYCLYC INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. 2010-02-04 US disclosed
WO-2010009155-A2 FUSED HETEROCYCLYC INHIBITOR COMPOUNDS GILEAD COLORADO, INC. (US) 2010-01-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029638-A1 FUSED HETEROCYCLYC INHIBITOR COMPOUNDS HDAC1, HDAC11, HDAC7 MAPT 2011/4885ALDH1A1 2855/4885HTT 1940/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.